Clinical Takeaway
Clinical trials show that cannabis-based products containing THC provide modest reductions in chronic pain compared to placebo, though the overall strength of evidence remains low to moderate. Products vary considerably by THC-to-CBD ratio, source, and delivery method, all of which influence both effectiveness and side effect profiles. Patients and clinicians should weigh these factors carefully, as benefits are real but modest and harms data are still accumulating.
#1 Cannabis-Based Products for Chronic Pain : An Updated Systematic Review.
Citation: Chou Roger et al.. Cannabis-Based Products for Chronic Pain : An Updated Systematic Review.. Annals of internal medicine. 2026. PMID: 41429020.
Design: 5 Journal: 3 N: 4 Recency: 3 Pop: 2 Human: 1 Risk: -2
This updated systematic review provides clinicians with current evidence on the efficacy and safety profile of cannabinoids across the THC-to-CBD spectrum for chronic pain management, addressing persistent clinical uncertainty about when these agents may be appropriate therapeutic options. By synthesizing randomized controlled trial data through rigorous dual review methodology, the study enables evidence-based prescribing decisions in a therapeutic area where cannabis products are increasingly requested by patients but lack clear clinical guidance.
Quality Gate Alerts:
- Preclinical only
Abstract: BACKGROUND: Benefits and harms of cannabinoids for chronic pain are uncertain. PURPOSE: To update an evidence synthesis on cannabinoids for chronic pain. DATA SOURCES: Ovid MEDLINE, PsycINFO, Embase, the Cochrane Library, and Scopus to 28 July 2025. STUDY SELECTION: Randomized placebo-controlled trials. DATA EXTRACTION: Data extraction, risk of bias, and strength of evidence were dually reviewed. Cannabinoids were categorized by tetrahydrocannabinol (THC)-to-cannabidiol (CBD) ratio (high, comparable, or low), source (synthetic, purified, extracted), and administration method. DATA SYNTHESIS: 25 short-term (1 to 6 months) randomized controlled trials (n = 2303; 64% neuropathic pain) assessed cannabinoids. Oral synthetic/purified high THC-to-CBD (THC only) may slightly reduce and oromucosal, extracted, comparable THC-to-CBD ratio products probably slightly reduce pain severity (pooled differences, -0.78 and -0.54 points, respectively, [0 to 10 scale]), with moderate or large increased dizziness, sedation, and nausea. Among THC-only products, nabilone moderately reduced pain severity but dronabinol did not (pooled differences, -1.59 and -0.23 points, respectively). Low THC-to-CBD interventions may not improve outcomes. Although low THC-to-CBD mixed THC/CBD products may increase dizziness, sedation, and nausea, CBD alone may not increase harms. LIMITATION: Variability within categories; lack of product details; unclear U.S. availability of studied products; restricted to English-language studies. CONCLUSION: Comparable and high THC-to-CBD ratio cannabinoid products may result in small improvements in pain and increased common adverse events during short-term treatment of primarily neuropathic pain; among high-ratio THC-only products, nabilone (but not dronabinol) reduced pain. Low THC-to-CBD products may not improve outcomes. Studies are needed on long-term outcomes and other cannabis product types. PRIMARY FUNDING SOURCE: Agency for Healthcare Research and Quality, U.S
💊 This updated systematic review helpfully synthesizes the current evidence on cannabinoids for chronic pain, yet the persistent uncertainty around efficacy and safety underscores the challenges inherent in this research domain. The categorization by THC-to-CBD ratios is methodologically sound, though clinicians should recognize that most trials remain relatively short-term, heterogeneous in patient populations, and often underpowered to detect meaningful differences in pain reduction or adverse events compared to placebo. Publication bias, variable product standardization, and the difficulty of blinding in cannabis research further complicate our ability to draw firm conclusions about which patients benefit most and at what doses. Given these limitations, cannabis-based products for chronic pain should remain a consideration in patients who have exhausted conventional analgesics or cannot tolerate them, rather than a first-line recommendation, with careful monitoring for cognitive effects, dependency, and drug interactions.